At Baxter’s recently expanded manufacturing facility dedicated to oncology products in Halle/Westfalen, Germany, all your parenteral needs are handled at one location, enabling processing solutions to fit your compound.
Literature / Brochures
Halle/Westfalen, Germany Facility Facts/Capabilities
Complex Sterile Manufacturing with More Than 60 Years of Oncology Experience
More Literature / Brochures by Baxter BioPharma Solutions
-
Brochures
-
Brochures
-
Brochures
-
Brochures
-
Brochures
-
Brochures
Bloomington, Indiana, USA Facility Facts/Capabilit
A Global Leader in Sterile Contract Manufacturing06.23.18
More Content From Baxter BioPharma Solutions
-
Seasonal Vaccine Manufacturing
There are three areas to evaluate when selecting an outsourcing partner for seasonal vaccine manufacturing.White Papers / Tech Papers Released on 02.12.2021
-
Leak Rate Testing for Freeze Dryers: A Scientific Approach
Assurance of the vacuum integrity of freezedryers used for the manufacture of sterile pharmaceutical products is essential for GMP operations.White Papers / Tech Papers Released on 03.08.2019
-
Pharmaceutical Development for ADCs: Not as Simple as ABC
...White Papers / Tech Papers Released on 03.08.2019
-
Enhanced Delivery Options for Injectables
Download the Enhanced Delivery Options Poster.Posters Released on 03.08.2019
-
BIOSIMILARS: Global Terminology, Strategy & Pathways
Download the Global Terminology, Strategy & Pathways PosterPosters Released on 03.08.2019
-
Considerations for Development of Lyophilized Biosimilar
This whitepaper discusses considerations for development of a lyophilized biosimilar, as well as a biosimilar case study.White Papers / Tech Papers Released on 11.01.2018
-
Your CMO for Sterile Injectables
85+ years of expertise in process and formulation development, technology transfer, and parenteral manufacturing.Videos Released on 10.19.2018
-
Baxter's BioPharma Solutions Business Recognized with ViE Award for Fifth Time
...News Releases Released on 07.06.2018
-
Manufacturing of Cytotoxic and Non-Cytotoxic Drugs in a Multiproduct Facility
When different drug products are produced in shared facilities, the potential for cross contamination is always a concern.White Papers / Tech Papers Released on 07.06.2018
-
Best Practices in Formulation and Lyophilization Development: Proteins, mAbs and ADCs
...White Papers / Tech Papers Released on 08.01.2016
-
Baxter BioPharma Solutions Wins the 2016 ISPE Facility of the Year Awards (FOYA)
In the Operational Excellence CategoryNews Releases Released on 02.22.2016
-
Baxter Completes Capacity Expansion at Halle, Germany Facility
Supports BioPharma Solutions’ Oncology Contract Manufacturing ServicesNews Releases Released on 11.12.2015
